PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

By PVI, PeerView Institute for Medical Education

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.

  1. 1.
    Manish A. Shah, MD, FASCO - Redrawing the Algorithm in Gastric and GEJ Cancers: Treatment Planning and Sequencing in the Era of Immunotherapy
  2. 2.
    Ian W. Flinn, MD, PhD - Visualizing the Present and Future of CLL: How Innovative Therapies and State-of-the-Art Combinations Are Transforming Patient Care
  3. 3.
    Ruben A. Mesa, MD, FACP - A Personalized Approach to Guide Risk-Adapted Treatment Decisions in Myelofibrosis: Applying the Latest Clinical Evidence on JAK Inhibitors and Novel Combination Therapies to Improve Patient Outcomes
  4. 4.
    Laura J. Zitella, MS, RN, ACNP-BC, AOCN - Taking the Fight to AML: Oncology Nurse Perspectives, Principles, and Practice in an Era of Innovative Therapies
  5. 5.
    Alok A. Khorana, MD, FACP, FASCO / Robert D. McBane, II, MD - Reducing the Global Burden of Cancer-Associated VTE: Applying Guideline-Concordant, Evidence-Based Care and Shared Decision-Making Strategies to Improve Patient Outcomes
  6. 6.
    Suzanne Lentzsch, MD, PhD - A New Treatment Era for Light Chain Amyloidosis: Interprofessional Lessons From a Center of Excellence
  7. 7.
    Bruce R. Korf, MD, PhD / Nicole J. Ullrich, MD, PhD, MMSci - Translating Science to Transform Clinical Practice: How MEK Inhibitors Are Changing the Treatment Landscape of NF1 and NF1-Associated Tumors
  8. 8.
    Deborah K. Armstrong, MD - The Expanding Advanced Ovarian Cancer Treatment Palette: Candid Conversations on Bringing PARP Inhibitors Into Clinical Practice
  1. 9.
    Sumanta Kumar Pal, MD - New Data and Clinical Context: An Update on Renal Cell Carcinoma Care in Early Through Advanced Disease
  2. 10.
    Jaffer A. Ajani, MD / Ian Chau, MD, FRCP - Gaining New Ground With Immunotherapy in the Management of Early and Advanced Gastrointestinal Cancers: Translating Progress Into Clinical Practice in Gastric, Esophageal, GEJ, and Colorectal Cancers
  3. 11.
    Gail J. Roboz, MD - Clinical Consults on Modern AML Therapy: Where Precision Care Meets Potent Therapeutics
  4. 12.
    Sara M. Tolaney, MD, MPH - Evaluating the Evidence and Parsing the Practicalities of Therapeutic Choices in Advanced and Early HR+ Breast Cancer: Expert Perspectives on CDK4 and 6 Inhibitors and Other Novel Agents
  5. 13.
    Jacob Sands, MD - Making the Most of Treatment Advances in SCLC: New Standards, Practicalities of Care, and Hope on the Horizon
  6. 14.
    Jason J. Luke, MD, FACP / Geoffrey T. Gibney, MD - Building Better Models for Melanoma Care: Continued Progress With Immunotherapy in Resectable and Unresectable Disease
  7. 15.
    Joyce O’Shaughnessy, MD - Expanding the Benefits of Checkpoint Inhibitors and Targeted Agents in the Treatment Arsenal for Triple-Negative Breast Cancer
  8. 16.
    Sara Hurvitz, MD - Making Progress in Early and Advanced HER2-Positive Breast Cancer: Leveraging HER2-Targeted Therapies and Modern Care Principles to Improve Clinical Outcomes and Health Equity
  9. 17.
    Matthew S. Davids, MD, MMSc - Pushing Therapeutic Boundaries in CLL: The Convergence of Targeted Therapy, Novel Combinations, and Precision Medicine in Patient Care
  10. 18.
    William G. Wierda, MD, PhD - New Standards for CLL Care With BTK Inhibitors: Using Evidence to Make Personalized Treatment Choices
  11. 19.
    Nicola Gökbuget, MD - Achieving Therapeutic Innovation in ALL: Insights on Modern Asparaginase Compounds in Pediatric, AYA, and Adult Patients
  12. 20.
    Toni K. Choueiri, MD - Rethinking the Care of Renal Cell Carcinoma: Expert Perspectives on Novel Agents, Combinations, and Sequencing Therapy
  13. 21.
    Karl D. Lewis, MD - Innovative Immunotherapy in Advanced Basal Cell Carcinoma: Evolving Science, Key Clinical Evidence, and Implications for Multidisciplinary Management
  14. 22.
    Matthew D. Galsky, MD - New and Emerging Therapeutic Strategies in Bladder Cancer: Updates in Early-Stage Disease and Beyond
  15. 23.
    Steven W. Pipe, MD - Envisioning the Future of Emerging Nonfactor Therapies in Hemophilia A and B: The Art and Science of RNA Interference
  16. 24.
    Rajiv Agarwal, MD, MS - HIF-PH Inhibitors: An Emerging Strategy for Managing Anemia in Patients With Chronic Kidney Disease
  17. 25.
    George L. Bakris, MD - Recognizing and Treating Hyperkalemia in Patients With Heart Failure and/or Chronic Kidney Disease: An Update for Hospitalists
  18. 26.
    Shanu Modi, MD - Navigating Shifts in the Treatment Landscape for Metastatic HER2-Positive Breast Cancer: Can New HER2-Targeted Therapies Address Unmet Needs and Offer Better Options for Challenging Patient Populations?
  19. 27.
    Sara M. Tinsley, PhD, APRN, AOCN - Therapeutic Advancements in Myelodysplastic Syndromes: Bridging the Gap Between Patient Safety and Quality Care Through the Latest Science and Evidence-Based Learning in Nursing Practice
  20. 28.
    Ronan J. Kelly, MD, MBA / Siva Raja, MD, PhD, FACS - Immune Checkpoint Inhibitor Therapy for Locally Advanced and Early-Stage Esophageal/GEJ Cancer: The Latest Evidence and Implications for Thoracic Surgeons and the Multidisciplinary Care Team
  21. 29.
    Laura S. Wood, RN, MSN, OCN / Sumanta Kumar Pal, MD - The New Therapeutic Era in Renal Cell Carcinoma: Essentials for Team-Based Patient Care
  22. 30.
    Brendon M. Stiles, MD - Immunotherapy as a Game-Changer in Multimodal Management of Locally Advanced and Earlier Stages of Lung Cancer
  23. 31.
    Lesley Camille Ballance, MSN, FNP-BC / Amy Goodrich, CRNP / Jill Lozensky, RN, BSN, OCN - Changing Times in DLBCL: Oncology Nurse Insight on the Practicalities of Antibody Therapy
  24. 32.
    Elizabeth A. Raetz, MD / Rachel Rau, MD - Meeting Therapeutic Challenges in Pediatric ALL: Expert Perspectives on the Use of Asparaginase Compounds
  25. 33.
    Matthew D. Galsky, MD - The Therapeutic Transformation of Bladder Cancer: Understanding Immune-, Targeted-, and Antibody-Based Models for Patient Care
  26. 34.
    Suresh S. Ramalingam, MD, FACP, FASCO / Arjun Balar, MD / Yelena Janjigian, MD - Revisiting PD-L1 as an Immunotherapy Biomarker Across the Cancer Spectrum: Current and Emerging Standards of Testing, Scoring, and Assay Interpretation
  27. 35.
    Bradley J. Monk, MD, FACS, FACOG / Angeles Alvarez Secord, MD, MHSc - Enhancing Personalized Medicine in Advanced Ovarian Cancer: Expert Guidance on Integrating the Latest Updates on PARP Inhibitors and Novel Therapeutic Innovations Into Your Clinical Practice
  28. 36.
    Amy Goodrich, CRNP - Making Modern Treatment Choices in CLL: Oncology Nurse Insights on the Patient Journey and the New Era of Care
  29. 37.
    Evan J. Lipson, MD - Analyzing the Pros and Cons of Standard and Alternative Dosing Regimens of Immunotherapies and Combinations in Modern Oncology Practice
  30. 38.
    "Joseph D. Khoury, MD, FCAP - Visualizing Progress for TP53-Mutant AML: A Pathology-Guided Journey Through Diagnostic Principles and Modern Treatment"
  31. 39.
    "Susana Banerjee, MBBS, MA, FRCP, PhD / William J. Gradishar, MD, FASCO, FACP / Maha Hussain, MD, FACP, FASCO
  32. 40.
    Kurt A. Schalper, MD, PhD / Shanu Modi, MD - HER2 and HER3 Alterations as Therapeutic Targets of Increasing Significance in Solid Tumors: Implications for Pathology and Oncology Practice
  33. 41.
    Matthew S. Johnson, MD, FSIR / Richard S. Finn, MD - At the Nexus of Locoregional and Systemic Liver Cancer Therapy: A Multidisciplinary Tumor Board on Improving Outcomes in Intermediate to Advanced HCC
  34. 42.
    Michael R. Bishop, MD - Betting on CAR-T Cell Therapy: Expert Perspectives on Effective Integration Strategies and Achieving Improved Outcomes Across Hematologic Cancers
  35. 43.
    Dara L. Aisner, MD, PhD / Joshua Bauml, MD / Paul A. VanderLaan, MD, PhD - Precision Decisions in Genomic Testing and Targeted Treatment of NSCLC
  36. 44.
    Naval Daver, MD - Optimizing Care for High-Risk Myeloid Cancers: Interprofessional Team Insights From a Center of Excellence
  37. 45.
    Jennifer Wargo, MD, MMSc - The Path Forward for Immunotherapy in Resectable Melanoma: Principles and Perspectives on Using Immune-Based Adjuvant and Neoadjuvant Therapy
  38. 46.
    Brian I. Rini, MD, FASCO - Optimizing Patient Outcomes in RCC Through Safe and Efficacious Use of Immuno-Oncology and Targeted Approaches: Teaming Up to Mitigate and Manage Adverse Events and Maximize Survival
  39. 47.
    Hossein Borghaei, DO, MS / Sanjay Mukhopadhyay, MD / Jonathan A. Nowak, MD, PhD - The Nuances of Immunotherapy Biomarker Testing in Solid Tumors: Unraveling Complexities and Overcoming Challenges to Improve Outcomes
  40. 48.
    Jay B. Wish, MD - Targeting Hypoxia-Inducible Factor Stabilization as a Treatment for Anemia in Chronic Kidney Disease: Examining the Current State of the Science
  41. 49.
    John M. Pagel, MD, PhD / Ian W. Flinn, MD, Ph - DConversations on the New Wave of Innovative Therapy in Follicular Lymphoma: Implications for Personalized Medicine
  42. 50.
    Alexander (Ander) Cohen, MB BS (Hons), MSc, MD, FRACP, FESC - New Insights: How Does Real-World Evidence Influence VTE Management? A Visual Exploration of Real-World Studies of DOACs

Listen to PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast now.

Listen to PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast in full in the Spotify app